Phase II Trial Results with Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer
CME INFORMATION

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians and basic scientists sojourn to the American Society of Clinical Oncology (ASCO) Annual Meeting to learn about recent clinical advances that yield alterations in state-of-the-art management for all tumor types. Attracting tens of thousands of attendees from every corner of the globe to both unveil and digest the latest research, ASCO is unmatched in attendance and clinical relevance. Results presented from ongoing trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all cancer medicine. Despite the importance of the conference, the demands of routine practice often limit the amount of time oncology clinicians can realistically dedicate to travel and learning. To bridge the gap between research and patient care, this CME activity will deliver a review of the key presentations from the ASCO Annual Meeting and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for diverse forms of cancer.

LEARNING OBJECTIVE
- Recall the results of new research on the efficacy and safety of the novel tyrosine kinase inhibitor cabozantinib (XL184) for patients with metastatic castration-resistant prostate cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/5MJCASCO2011/Prostate/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

William K Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

Ezra M Greenspan, MD
Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine

Advisory Committee: Sanofi; Consulting Agreements: Dendreon Corporation, Pfizer Inc.

Christopher J Logothetis, MD
Chairman/Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

Research To Practice Staff and External Reviewers
— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This program is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation and Genentech BioOncology.

Last review date: September 2011
Expiry date: September 2012
To go directly to the slides and investigator commentary for the featured abstracts, click here.

The electric pace of oncology in 2011 means that most busy practitioners barely have time to read abstracts, let alone dive into journal articles and watch or attend meeting presentations. Addressing that challenge, this latest experiment in cancer education attempts to provide our quickest take possible on the most memorable presentations from ASCO 2011. This first issue focuses on solid tumors (hematologic cancers will be coming next week), and for each of the presentations summarized below we have created a brief, clickable slide set reviewing the most essential findings and providing the perspectives of clinical investigators (presented on the last slide of each set). Here we go:

1. **Vemurafenib and ipilimumab in melanoma**
   Two plenary papers on Phase III trials with these agents showed important survival benefits (ab LBA4 and LBA5). The findings and recent FDA approval of both of these agents heighten the importance of BRAF V600E mutation testing and create a challenging choice between these two interesting novel compounds as first-line therapy for patients with tumors harboring these mutations.

2. **GI cancers: Adjuvant imatinib in GIST; neoadjuvant treatment of rectal cancer**
   Another compelling plenary paper (ab LBA1) reported a trial in patients with high-risk GIST revealing that 3 years of adjuvant imatinib resulted in much better PFS and OS than 1 year. Importantly, in both groups relapses started occurring 6 months after the discontinuation of treatment, suggesting the need for longer-duration or perhaps indefinite imatinib.

   Also in GI cancer, 2 trials (ab 3503 and 3504) addressed a couple of old, lingering questions in terms of the choice of chemotherapy to pair with radiation therapy in rectal cancer. Bottom line: There doesn’t seem to be a current role for neoadjuvant oxaliplatin, and it’s pretty challenging to think of a good reason to use 5-FU instead of capecitabine.
3. Important Phase I-II studies on novel agents
In our nominee for most exciting ASCO data set (ab 4516), the Met/VEGFR2 TKI cabozantinib (formerly XL 184) in prostate cancer produced some of the most stunning outcomes seen in this or any other solid tumor, including dramatic improvements evident on bone scans often associated with major symptom palliation.

A close second to the cabozantinib paper (ab 7525) and one that kept the faculty at our recent lung cancer Think Tank buzzing demonstrated that pan-EGFR blockade with the irreversible TKI afatinib combined with cetuximab resulted in significant responses in patients with advanced NSCLC resistant to an EGFR TKI, including those with T790M mutations.

Another encouraging NSCLC paper (ab 7505) evaluated the monoclonal antibody MetMAb and demonstrated improved PFS in the 52% of patients with Met overexpression.

4. Iniparib in triple-negative breast cancer
We all knew it was coming, but the biggest downer of the meeting (ab 1007) was the pretty much negative study — presented by the diminutive genius Joyce O'Shaughnessy — of iniparib plus chemo in advanced TNBC. These disappointing findings left many scratching their heads and have forced researchers back to the drawing board in an attempt to figure out why this putative PARP inhibitor worked in the Phase II but not the Phase III setting.

5. Reinforcement of the new lung adenocarcinoma advanced-disease paradigm
The PARAMOUNT trial (ab CRA7510) again supported the role of some type of maintenance strategy after first-line chemo with or without bev, this time the “continuation” of pemetrexed, and while we await Phase III data from the related PointBreak trial, pem/carbo with or without bev followed by pem and/or bev maintenance are commonly employed nonprotocol approaches.

In a similar vein, the EURTAC study (ab 7503) again demonstrated that for patients with EGFR mutation-positive advanced lung cancer, an EGFR TKI results in better short-term outcomes than chemo.

6. Bevacizumab with chemotherapy in breast and ovarian cancer
Two neoadjuvant breast trials (ab LBA1005 and 1006) demonstrated more path CRs with bev, and a reanalysis of the RIBBON 2 trial evaluating this anti-angiogenic agent in the second-line setting revealed a doubling of response rates for patients with triple-negative disease (ab 1010).
In recurrent ovarian cancer, chemo plus bev with bev maintenance until progression resulted in longer PFS (ab LBA5007), and more follow-up from the ICON7 “adjuvant” trial (ab LBA5006) continued to show a slowing of disease progression with chemo/bev followed by bev maintenance. However, as yet no impact on survival has been observed. What this means in both cancers outside a protocol setting and from a regulatory/reimbursement perspective continues to be vociferously debated.

Next up on our condensed ASCO highlights reel: Liquid tumor snippets.

Neil Love, MD
Research To Practice
Miami, Florida
Phase II Trial Results with Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer

Presentation discussed in this issue

Hussain M et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Proc ASCO 2011;Abstract 4516.

Slides from a presentation at ASCO 2011 and comments from William K Oh, MD and Christopher J Logothetis, MD

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial

Hussain M et al.
Proc ASCO 2011;Abstract 4516.
**Introduction: Cabozantinib**

- Cabozantinib is a tyrosine kinase inhibitor (TKI) that blocks MET and VEGFR2 in vivo.
- MET and its ligand, HGF, drive tumor cell invasion and metastasis.
- MET and VEGFR2 synergize to promote angiogenesis.
- Bone metastases are associated with high levels of MET expression.
  - HGF and VEGF direct cross talk between tumor cells, osteoblasts and osteoclasts.
- In prostate cancer:
  - Preclinically androgen deprivation increases MET expression.
  - MET increases with progression and metastasis in bone and lymph nodes.

Hussain M et al. Proc ASCO 2011; Abstract 4516.

---

**XL184-203: Phase II Trial Design**

12-Week Lead-In Stage:
Open-label cabozantinib 100 mg PO, QD

Week 12
Tumor Staging

- PR or CR
- SD
- PD

Open-Label Extension
Cabozantinib

Blinded Randomized Stage
Cabozantinib vs placebo (1:1)

Discontinue cabozantinib

Discontinue cabozantinib

Unblind at progression

Placebo Cross-Over to cabozantinib

CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease

**Primary objective:** Evaluate the efficacy of cabozantinib in multiple solid tumors (Lead-in stage: Objective response rate (mRESIST 1.0), Randomized stage: Progression-free survival (PFS))

**Secondary objectives:** Safety and tolerability; access potential pharmacodynamic effects of cabozantinib

Hussain M et al. Proc ASCO 2011; Abstract 4516.
XL184-203: Tumor Regression in Soft Tissue Lesions

- 74% of patients have shown evidence of tumor regression
- PSA changes did not correlate with radiographic changes

N = 151 patients with ≥ post-baseline assessment

With permission from Hussain M et al. Proc ASCO 2011;Abstract 4516.

XL184-203: Bone Scan Effects — Representative Images

Each patient achieved partial response and pain improvement.

With permission from Hussain M et al. Proc ASCO 2011;Abstract 4516.
XL184-203: Correlation of Bone Scan Resolution with Clinical Effects

Bone Scan Evaluation
- **Partial or Complete Resolution**
- **Stable or PD**

<table>
<thead>
<tr>
<th></th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Lesion Regression</td>
<td>78%</td>
</tr>
<tr>
<td>PFS at 6 Months</td>
<td>58%</td>
</tr>
<tr>
<td>Pain Improvement*</td>
<td>61%</td>
</tr>
<tr>
<td>Narcotics Decrease</td>
<td>35%</td>
</tr>
<tr>
<td>CTx Reduction ≥ 50%</td>
<td>43%</td>
</tr>
</tbody>
</table>

* Limited to patients treated with narcotics at baseline

With permission from Hussain M et al. Proc ASCO 2011;Abstract 4516.

XL184-203: PFS — Overall and by Docetaxel Pretreatment Status

**Overall median PFS 29: weeks**
(Excludes patients randomized to placebo)

<table>
<thead>
<tr>
<th>Pretreatment Status</th>
<th>Median PFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Docetaxel-Naïve (n = 90)</td>
<td>29 weeks</td>
</tr>
<tr>
<td>Docetaxel-Pretreated (n = 64)</td>
<td>24 weeks</td>
</tr>
</tbody>
</table>

With permission from Hussain M et al. Proc ASCO 2011;Abstract 4516.
**XL184-203: Select Adverse Events (n = 171)**

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>All grades</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>63%</td>
<td>16%</td>
<td>—</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>49%</td>
<td>5%</td>
<td>—</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>46%</td>
<td>2%</td>
<td>—</td>
</tr>
<tr>
<td>Nausea</td>
<td>44%</td>
<td>4%</td>
<td>—</td>
</tr>
<tr>
<td>PPE syndrome</td>
<td>27%</td>
<td>6%</td>
<td>—</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26%</td>
<td>4%</td>
<td>—</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>20%</td>
<td>1%</td>
<td>—</td>
</tr>
<tr>
<td>Hypertension</td>
<td>19%</td>
<td>6%</td>
<td>—</td>
</tr>
<tr>
<td>Thrombosis venous</td>
<td>8%</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Gastrointestinal perforation</td>
<td>1%</td>
<td>1%</td>
<td>1%</td>
</tr>
</tbody>
</table>

* Most frequently reported AEs during lead-in stage regardless of causality

Hussain M et al. Proc ASCO 2011;Abstract 4516.

---

**Author Conclusions**

- Cabozantinib has substantial antitumor activity in patients with mCRPC and progressive disease.
  - Overall objective disease control at week 12: 68%
  - Measurable disease regression: 74%
  - Complete or partial resolution of bone scans: 76%
  - Pain improvement in patients with pain at baseline: 67%
  - Overall median progression-free survival: 29 weeks
    - Significant PFS improvement post-randomization

- Cabozantinib has a moderate but manageable adverse event profile similar to other TKIs.

- Cabozantinib is being evaluated in docetaxel-pretreated patients with mCRPC (NCT00940225).

Hussain M et al. Proc ASCO 2011;Abstract 4516.
Investigator Commentary: The Phase II Trial Results with Cabozantinib in mCRPC

This randomized discontinuation trial received much attention because of the high response rates and substantial proportion of patients whose bone scans normalized. The data showed correlation between normalization of bone scans and improvement in pain and PSA response. However, we know that bone scans are not the best indicators of disease response to treatment in prostate cancer, so we are concerned that this may not be a real effect.

Cabozantinib is an exciting drug that appears to target MET in addition to VEGF. It is theorized that the MET pathway may be an escape mechanism for VEGF, so blocking both pathways may lead to the enhanced response we are seeing with this agent. Only a third to half of patients with prostate cancer would have met the trial eligibility criterion of having a measurable soft tissue lesion, but the response rate to measurable disease was high. The rate of partial response by RECIST was only 4%, although the waterfall plot showed that most patients experienced shrinkage of their tumors, which was better than the stable disease expected. This suggests that we are using imperfect tools to measure prostate cancer lesions and response to therapy.

William K Oh, MD
Research To Practice®

Additional Investigator Commentary on Bone Scan Effects Reported with Cabozantinib in mCRPC

Another interesting aspect of this study of the c-MET and VEGFR2 inhibitor cabozantinib was the striking changes in bone scans. This effect happened rapidly and was linked to a reduction in bone pain. Those patients who had an improvement in bone scan and reduction in bone pain seem to be the ones whose disease is controlled longest and best with cabozantinib.

Some patients also experienced regression of soft tissue metastases. So it’s clear that cabozantinib does much more than just alter images of bone scans. It causes favorable events in the cancer as well.

Precisely how this agent is working remains unclear. c-MET expression is increased in the osteoblasts adjacent to the tumor, and it may be that the antitumor activity results from blocking c-MET function in osteoblasts. I don’t believe all the changes can be attributed to just changes in the bone scan. These patients benefit too much for too long, and we see soft tissue regression.

Christopher J Logothetis, MD
Research To Practice®